Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: pain therapeutics - AstraZeneca

Next Previous
Drug Profile

Research programme: pain therapeutics - AstraZeneca

Alternative Names: AZ 09; AZ 11760788; AZ 12048189; AZ 12099548; AZ 1297442; AZ 599; AZD 7903; AZD 9335

Latest Information Update: 04 Nov 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class 3-ring heterocyclic compounds; Indoles; Isoxazoles; Pyridines; Sulfonamides
  • Mechanism of Action Bradykinin B2 receptor antagonists; Cannabinoid receptor CB1 agonists; Nav1.7 voltage-gated sodium channel inhibitors; Sodium channel antagonists; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammatory pain; Neuropathic pain
  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-pain in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada (IV, Infusion)
  • 31 Aug 2012 Pharmacodynamics data from a Preclinical trial in Neuropathic pain presented at the 14th World Congress on Pain (WCP-2012)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top